The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden

• DOI: 10.1007/s40273-021-01015-8
• Publication Date: 2021-06-03T01:21:54Z
• Authors: Fredrik O. L. Nil...; Sandra T. Asanin; Elizabeth T. Masters; Laura Iadeluca; Chrissy Almond; Miranda Cooper; Sarah Smith
• Keywords: Sweden; Lung Neoplasms; Lactams; Cost-Benefit Analysis; Aminopyridines; Protein-Tyrosine Kinases; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Carcinoma, Non-Small-Cell Lung; Proto-Oncogene Proteins; Humans; Pyrazoles; Anaplastic Lymphoma Kinase; Original Research Article; Quality-Adjusted Life Years

Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) tyrosine inhibitor (TKI) with efficacy in patients ALK-rearranged non-small-cell lung cancer (NSCLC) previously treated second-generation ALK or first- and inhibitors. We examined the cost-effectiveness of second- third-line+ (2L+ 3L+) lorlatinib Sweden, versus chemotherapy.